PT625204E - Terapeutica da hepatite - Google Patents

Terapeutica da hepatite

Info

Publication number
PT625204E
PT625204E PT93904901T PT93904901T PT625204E PT 625204 E PT625204 E PT 625204E PT 93904901 T PT93904901 T PT 93904901T PT 93904901 T PT93904901 T PT 93904901T PT 625204 E PT625204 E PT 625204E
Authority
PT
Portugal
Prior art keywords
hepatitis
infections
therapeutics
hepatitis therapeutics
treating hepatitis
Prior art date
Application number
PT93904901T
Other languages
English (en)
Inventor
Douglas J Jolly
Stephen M W Chang
William Tsung-Liang Lee
Kay Townsend
Joann O'dean
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25256972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT625204(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of PT625204E publication Critical patent/PT625204E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Catching Or Destruction (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT93904901T 1992-02-04 1993-02-04 Terapeutica da hepatite PT625204E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83041792A 1992-02-04 1992-02-04

Publications (1)

Publication Number Publication Date
PT625204E true PT625204E (pt) 2002-10-31

Family

ID=25256972

Family Applications (1)

Application Number Title Priority Date Filing Date
PT93904901T PT625204E (pt) 1992-02-04 1993-02-04 Terapeutica da hepatite

Country Status (10)

Country Link
EP (1) EP0625204B1 (pt)
JP (3) JPH07503615A (pt)
AT (1) ATE219522T1 (pt)
AU (2) AU3610293A (pt)
CA (1) CA2128896A1 (pt)
DE (1) DE69332045T2 (pt)
DK (1) DK0625204T3 (pt)
ES (1) ES2174845T3 (pt)
PT (1) PT625204E (pt)
WO (1) WO1993015207A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297048B1 (en) 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
DK0992580T3 (da) 1993-11-04 2005-07-11 Innogenetics Nv Epitoper på human T-celler, som er immundominante for hepatitis C-virus
DE69535669T2 (de) 1994-05-09 2008-12-04 Oxford Biomedica (Uk) Ltd. Retrovirale vektoren mit verminderter rekombinationsrate
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6235888B1 (en) 1994-10-05 2001-05-22 The General Hospital Corporation Hepatitis C virus vaccine
NZ296304A (en) * 1994-10-05 1999-06-29 Apollon Hepatitis c vaccine components
US5856169A (en) * 1995-02-21 1999-01-05 Thomas Jefferson University Isoforms of human interleukin-1β converting enzyme and methods of using the same
RU2189254C2 (ru) * 1995-06-06 2002-09-20 Америкэн Хоум Продактс Корпорэйшн Вакцины против вирусов гепатита
ATE386811T1 (de) 1996-04-05 2008-03-15 Novartis Vaccines & Diagnostic Alphaviren-vektors mit eine reduzierte inhibierung der synthese von zellmakromolekülen
SI1077722T1 (sl) 1998-05-22 2007-02-28 Ottawa Health Research Inst Metode in produkti za induciranje sluznicne imunosti
NZ540098A (en) 2002-10-29 2008-09-26 Coley Pharmaceutical Group Ltd Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
JP4474198B2 (ja) * 2004-05-19 2010-06-02 株式会社日立ハイテクノロジーズ Ｃ型肝炎ウイルス恒温増幅用プライマー
EP2185195A2 (en) * 2007-08-16 2010-05-19 Tripep Ab Immunogen platform
KR20200006177A (ko) * 2011-03-02 2020-01-17 제롬 쉔타그 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988000971A1 (en) * 1986-08-01 1988-02-11 Commonwealth Scientific And Industrial Research Or Recombinant vaccine
WO1988006185A1 (en) * 1987-02-11 1988-08-25 Scripps Clinic And Research Foundation Retroviral expression vectors and methods for producing hbv antigens
IE911130A1 (en) * 1990-04-04 1991-10-09 Protos Hepatitis c protease inhibitors
WO1991015771A1 (en) * 1990-04-04 1991-10-17 Chiron Corporation Combinations of hepatitis c virus (hcv) antigens for use in immunoassays for anti-hcv antibodies
CA2045326A1 (en) * 1990-06-25 1991-12-26 Hiroto Okayama Non-a, non-b, hepatitis virus particles
CA2049679C (en) * 1990-08-24 2005-06-21 Sushil G. Devare Hepatitis c assay utilizing recombinant antigens

Also Published As

Publication number Publication date
DE69332045D1 (de) 2002-07-25
ATE219522T1 (de) 2002-07-15
JP2000154152A (ja) 2000-06-06
JP2003055265A (ja) 2003-02-26
EP0625204B1 (en) 2002-06-19
AU7530996A (en) 1997-02-20
ES2174845T3 (es) 2002-11-16
DE69332045T2 (de) 2002-10-17
WO1993015207A2 (en) 1993-08-05
DK0625204T3 (da) 2002-07-15
JPH07503615A (ja) 1995-04-20
WO1993015207A3 (en) 1994-01-06
CA2128896A1 (en) 1993-08-05
EP0625204A1 (en) 1994-11-23
AU3610293A (en) 1993-09-01

Similar Documents

Publication Publication Date Title
PT625204E (pt) Terapeutica da hepatite
GB2272443A (en) Hepatitis C diagnostics and vaccines
BR9712488A (pt) Anticorpo anti-hm 1.24 humano remodelado
NO940660L (no) HLA - begrensete Hepatit B virus CTL-epitoper
AU1471797A (en) Hybrid protein between CS from plasmodium and HBsAG
NO941310D0 (no) Sammensetning og fremgangsmåte for behandling av hepatitt C
ES2063515T3 (es) Ifn-alfa o-glucosilados.
DE60039715D1 (de) Hcv-impfstoff zusammensetzungen
LU88364I2 (fr) HBVax Vaccin recombinant contenant une protéine HBsAG pour une immunisation active contre des infections dues à l'hépatite B.
DK0588578T3 (da) Immunogener
HU9301794D0 (en) Medical preparative for treating chronical viral diseases of liver as well qs method for preparing said medicament
NO912825L (no) Fremgangsmaate for fremstilling av kokonjugatvaksiner omfattende im munogent protein, hiv-beslektede peptider og anioniske grupper.
GR3026519T3 (en) New method of treating depression
ATE223235T1 (de) Chitosan induzierte verstärkung
PT600396E (pt) Vacinas contra protozoarios intestinais
NL300336I1 (nl) Vaccin tegen de bof dat een jeryl-lynn virusstam bevat
PH31116A (en) Methods for the treatment of infection caused by hepatitis B virus (hbv).
DE69333730D1 (de) Impfstoff, der acemannan als adjuvans enthält
FI861966A (fi) Renad och tre gaonger klonad hepatit-a-virus.
DK0831881T3 (da) CETP til forøgelse af HDL-cholesterolniveau
DK0676965T3 (da) Fremgangsmåde til at reducere immunogeniciteten af variable regioner på antistoffer
DE69130953D1 (de) Immunverstärkung von impfstoffen, besonders von impfstoffen gegen schweinepleuropneumonie
ATE128733T1 (de) Monoklonale antikörper gegen hiv gp120.
IT8221787A0 (it) Procedimento per la preparazione di antigene superficiale puro dell'epatite b da plasma umano.
PT589348E (pt) Processo para a quantificacao imunoquimica de antigenios inactivados, imunoreactivos